179 related articles for article (PubMed ID: 12102627)
1. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors.
Wang D; Pechar M; Li W; Kopecková P; Brömme D; Kopecek J
Biochemistry; 2002 Jul; 41(28):8849-59. PubMed ID: 12102627
[TBL] [Abstract][Full Text] [Related]
2. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.
Guay J; Falgueyret JP; Ducret A; Percival MD; Mancini JA
Eur J Biochem; 2000 Oct; 267(20):6311-8. PubMed ID: 11012686
[TBL] [Abstract][Full Text] [Related]
3. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases.
Bossard MJ; Tomaszek TA; Levy MA; Ijames CF; Huddleston MJ; Briand J; Thompson S; Halpert S; Veber DF; Carr SA; Meek TD; Tew DG
Biochemistry; 1999 Nov; 38(48):15893-902. PubMed ID: 10625455
[TBL] [Abstract][Full Text] [Related]
5. Water-soluble HPMA copolymer--prostaglandin E1 conjugates containing a cathepsin K sensitive spacer.
Pan H; Kopecková P; Wang D; Yang J; Miller S; Kopecek J
J Drug Target; 2006 Jul; 14(6):425-35. PubMed ID: 17092842
[TBL] [Abstract][Full Text] [Related]
6. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
7. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
Black WC; Percival MD
Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
[TBL] [Abstract][Full Text] [Related]
8. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
[TBL] [Abstract][Full Text] [Related]
9. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
10. Functionalized semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] for protein modification.
Lu ZR; Kopecková P; Wu Z; Kopecek J
Bioconjug Chem; 1998; 9(6):793-804. PubMed ID: 9815174
[TBL] [Abstract][Full Text] [Related]
11. Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.
Marquis RW; Ru Y; Yamashita DS; Oh HJ; Yen J; Thompson SK; Carr TJ; Levy MA; Tomaszek TA; Ijames CF; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; D'Alessio KJ; McQueney MS; Veber DF
Bioorg Med Chem; 1999 Apr; 7(4):581-8. PubMed ID: 10353637
[TBL] [Abstract][Full Text] [Related]
12. Affinity selection to papain yields potent peptide inhibitors of cathepsins L, B, H, and K.
Bratkovic T; Lunder M; Popovic T; Kreft S; Turk B; Strukelj B; Urleb U
Biochem Biophys Res Commun; 2005 Jul; 332(3):897-903. PubMed ID: 15913550
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K and the design of inhibitors of cathepsin K.
Yamashita DS; Dodds RA
Curr Pharm Des; 2000 Jan; 6(1):1-24. PubMed ID: 10637370
[TBL] [Abstract][Full Text] [Related]
14. Human cathepsin X: A cysteine protease with unique carboxypeptidase activity.
Nägler DK; Zhang R; Tam W; Sulea T; Purisima EO; Ménard R
Biochemistry; 1999 Sep; 38(39):12648-54. PubMed ID: 10504234
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers.
Wang D; Kopecková JP; Minko T; Nanayakkara V; Kopecek J
Biomacromolecules; 2000; 1(3):313-9. PubMed ID: 11710118
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors.
Turk B; Turk V; Turk D
Biol Chem; 1997; 378(3-4):141-50. PubMed ID: 9165064
[TBL] [Abstract][Full Text] [Related]
17. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
18. Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis.
Welss T; Sun J; Irving JA; Blum R; Smith AI; Whisstock JC; Pike RN; von Mikecz A; Ruzicka T; Bird PI; Abts HF
Biochemistry; 2003 Jun; 42(24):7381-9. PubMed ID: 12809493
[TBL] [Abstract][Full Text] [Related]
19. Acyclic cyanamide-based inhibitors of cathepsin K.
Barrett DG; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Payne JA; Shewchuk LM; Willard DH; Wright LL
Bioorg Med Chem Lett; 2005 Jun; 15(12):3039-43. PubMed ID: 15896958
[TBL] [Abstract][Full Text] [Related]
20. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.
Kasuya Y; Lu ZR; Kopecková P; Tabibi SE; Kopecek J
Pharm Res; 2002 Feb; 19(2):115-23. PubMed ID: 11883637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
